Kelly Andrzejewski
Neurology · Rochester, NYNPI 1295051886
Payments from drug & device makers
Across 588 payments — averaging $1014.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$195K
- Neurocrine Biosciences, Inc.$180K
- Teva Pharmaceuticals USA, Inc.$129K
- Boston Scientific$49K
- H. Lundbeck A S$17K
- AbbVie$16K
- plus $11K from 22 others
Across 3 payments — averaging $425.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lundbeck LLC$1K
What the payments were for
- Consulting fees$11,3189%
- Speaking & faculty fees$102,04979%
- Travel & lodging$7,8166%
- Food & beverage$7,3596%
- Education$5580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 8 | $195,331 |
| Neurocrine Biosciences, Inc. | 185 | $179,993 |
| Teva Pharmaceuticals USA, Inc. | 181 | $128,872 |
| Boston Scientific | 59 | $48,870 |
| H. Lundbeck A S | 8 | $16,740 |
| AbbVie | 45 | $15,720 |
| Lundbeck LLC | 9 | $4,789 |
| Acorda Therapeutics, Inc | 7 | $2,991 |
| Medtronic(2 entities) | 29 | $1,828 |
| MDD US Operations, LLC | 17 | $292 |
| Abbott | 12 | $234 |
| CSL Behring | 3 | $98 |
| Supernus Pharmaceuticals, Inc. | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $69 |
| Merz Pharmaceuticals, LLC | 2 | $67 |
| Grifols USA, LLC | 2 | $51 |
| Livanova USA, Inc. | 2 | $47 |
| Greenwich Biosciences, Inc. | 1 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $30 |
| SK Life Science, Inc. | 1 | $27 |
| AstraZeneca | 1 | $26 |
| UCB, Inc. | 1 | $25 |
| Revance Therapeutics, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $20 |
| PTC Therapeutics, Inc. | 1 | $19 |
| GE HealthCare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$52,919
- AUSTEDO$43,198
- Duopa$15,020
- NORTHERA$4,642
- GENERAL DBS$2,907
- INBRIJA$2,825
- ACTIVA$838
- PERCEPT PC BRAINSENSE$267
- ACTIVA PC$110
- VERCISE$106
How this compares
$596,375 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 80 | $1,314,064 |
| Austedo XrDeutetrabenazine | 47 | $536,207 |
| NuplazidPimavanserin Tartrate | 58 | $322,229 |
| RytaryCarbidopa/Levodopa | 143 | $242,834 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 574 | $41,818 |
| Rasagiline Mesylate | 82 | $18,219 |
| Entacapone | 53 | $16,105 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 201 | $9,099 |
| OngentysOpicapone | 13 | $7,624 |
| Rivastigmine | 27 | $5,964 |
| Carbidopa | 19 | $5,587 |
| AmantadineAmantadine Hcl | 80 | $5,480 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 12 | $3,896 |
| Primidone | 74 | $3,357 |
| Clonazepam | 121 | $2,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $128,872 | $1,850,271127 claims |
| Acadia Pharmaceuticals IncNuplazid | $30 | $322,22958 claims |
| Amneal Pharmaceuticals LLCRytary | $69 | $242,834143 claims |
| Neurocrine Biosciences, Inc.Ongentys | $179,993 | $7,62413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in Rochester
- Kathleen MungerRochester$1.1M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.